In the first nine months of 2024, Teva reported revenue of $12.3 billion, up 8.1% from the corresponding period of last year.
Last quarter Teva raised 2024 revenue guidance to $16-16.4 billion, up 2.5% from 2023 and a return to growth after five years ...